256 related articles for article (PubMed ID: 10600331)
1. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
Logan TF; Gooding W; Kirkwood JM; Shadduck RK
Exp Hematol; 1996 Jan; 24(1):49-53. PubMed ID: 8536792
[TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
[TBL] [Abstract][Full Text] [Related]
4. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
5. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
[TBL] [Abstract][Full Text] [Related]
6. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
9. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.
Flohé S; Lendemans S; Selbach C; Waydhas C; Ackermann M; Schade FU; Kreuzfelder E
Crit Care Med; 2003 Oct; 31(10):2462-9. PubMed ID: 14530752
[TBL] [Abstract][Full Text] [Related]
10. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.
Siena S; Di Nicola M; Bregni M; Mortarini R; Anichini A; Lombardi L; Ravagnani F; Parmiani G; Gianni AM
Exp Hematol; 1995 Dec; 23(14):1463-71. PubMed ID: 8542932
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinoma cells influence differentiation of Lin-CD45RA- dendritic cell precursors into two mature subtypes in vitro.
Chen LL; Ye F; Yu Y; Chen HZ; Zhang WW; Lü WG; Xie X
Gynecol Oncol; 2009 Jan; 112(1):199-204. PubMed ID: 19022493
[TBL] [Abstract][Full Text] [Related]
12. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells].
Meng FY; Xu B; Sun J; Yang Y; Niu JN
Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
14. [The Langerhans cell: from in vitro production to use in cellular immunotherapy].
Schmitt D
J Soc Biol; 2001; 195(1):69-74. PubMed ID: 11530504
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response.
Eksioglu EA; Mahmood SS; Chang M; Reddy V
Exp Hematol; 2007 Aug; 35(8):1163-71. PubMed ID: 17562355
[TBL] [Abstract][Full Text] [Related]
16. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma.
Zijlmans HJ; Fleuren GJ; Baelde HJ; Eilers PH; Kenter GG; Gorter A
Cancer; 2007 Feb; 109(3):556-65. PubMed ID: 17177206
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
18. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral granulocyte-macrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain.
Mausberg AK; Jander S; Reichmann G
Glia; 2009 Sep; 57(12):1341-50. PubMed ID: 19229994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
